NHS NEL
Demonstration Formulary
Demonstration Formulary
6 Endocrine system
06-06-02 Denosumab
| Denosumab Prolia® |
|
Formulary
|
Dudley
Sandwell
Walsall
Wolverhampton
|
 ESCA: Denosumab (Prolia)-Sandwell only NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
|
with RiCaD | Denosumab Xgeva® |
|
Formulary
|
| For specialist use only in line with NICE TA265 |
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 ) |
|
Links
- DVLA guidance
- ESCA: Denosumab (Prolia)-Sandwell only
- ESCA: Ibandronic acid 50mg-Sandwell only
- ESCA: Sodium clodronate-Sandwell only
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA; Bisphosphonates: atypical femoral fractures
- NICE Guidance on prescribing
- NICE NG28: Type 2 diabetes in adults: management
- NICE TA 791: Romosozumab for treating severe osteoporosis
- NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160: Osteoporosis - primary prevention- NICE TA160: Osteoporosis - Primary Prevention
- NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
- NICE TA161: Osteoporosis - secondary prevention (including Teriparatide)
- NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
- NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 )
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464:Bisphosphonates for treating osteoporosis
- NOGG Osteoporosis - information for patients
- NOGG Osteoporosis Clinical Guideline Executive Summary
- NOGG Pocket Guide for Heathcare Professionals - Osteoporosis
- TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
UKMI Q&A: Proton pump inhibitor interaction with bisphosphonates? -